Ustekinumab for the treatment of Crohn's disease. - Wikidata - wikimedia - TriplyDB

Ustekinumab for the treatment of Crohn's disease.

Ustekinumab for the treatment of Crohn's disease.

http://www.wikidata.org/entity/Q30390909

about

Positioning ustekinumab in Crohn's disease: from clinical evidence to clinical practice.The current therapeutic options for Crohn's disease: from medical therapy to intestinal transplantation.

P2860

Q38748380-3FFC2EAB-33D0-494B-BD92-58C994A91C1A Q47798734-D953E7FE-6CDD-4897-9281-442716ABC8EE

P2860

Ustekinumab for the treatment of Crohn's disease.

http://www.wikidata.org/entity/Q30390909

description

2016 nî lūn-bûn

@nan

2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Ustekinumab for the treatment of Crohn's disease.

@ast

Ustekinumab for the treatment of Crohn's disease.

@en

type

label

Ustekinumab for the treatment of Crohn's disease.

@ast

Ustekinumab for the treatment of Crohn's disease.

@en

prefLabel

Ustekinumab for the treatment of Crohn's disease.

@ast

Ustekinumab for the treatment of Crohn's disease.

@en

P1433

Q30390909-471B3E7B-7B97-41DE-AF51-69054AE60EFE

P1476

Q30390909-90055F70-2D57-4683-A6FA-3558C9D023CC

P2093

Q30390909-31F21FBA-5EC0-47F2-AFA7-EC642D06A959

Q30390909-9B6B1D62-5390-4BFD-BF70-C58607CF9067

P2860

Q30390909-0E97A076-C3ED-4A66-B516-87FBD9FD8B01

Q30390909-0FDCFAA1-A673-4CAF-9214-0E5352A45526

Q30390909-18376D0E-28A9-45E2-A05D-5E0E03AE8BCD

Q30390909-2041F3D6-6F4A-4140-A8DE-067DF1214F74

Q30390909-216B053F-4C13-4E25-9CF6-1C0B3FB4C62E

Q30390909-23D20132-874E-4AC1-96A9-80EAD402204A

Q30390909-286FF7A2-E8D3-46C7-8215-C8F48FBD74E9

Q30390909-38E62B5B-C049-43AB-BCC0-FE8772F25F98

Q30390909-3C5F17C9-8736-4211-ACFE-242ECB1E4A7E

Q30390909-4107B30C-66DE-42F8-A2E8-C626576FEAE9

P304

Q30390909-FA512084-FA7F-4171-81F9-17B536938471

P31

Q30390909-B98E9B35-F5BE-4A1C-8E0A-D6B9BDED7758

P356

Q30390909-C4CA8B49-42DB-4DA8-8E78-9A51E297765A

P433

Q30390909-F33E2ADA-1508-42FF-A0CD-8DCAF93D9631

P478

Q30390909-B8A06091-2E24-4A2F-AB3E-800A992BCCE6

P577

Q30390909-135A0096-8CA4-41CB-B16E-809E921369BB

P698

Q30390909-AF1E2EAB-0EDC-49F7-AC59-570AA1164B48

P921

Q30390909-8F7B50DF-BA9C-4199-A52B-D85B75D6EB86

P356

17474124.2016.1215912

P1433

Expert Review of Gastroenterology & Hepatology

P1476

Ustekinumab for the treatment of Crohn's disease.

@en

P2093

Laura E Targownik

http://www.w3.org/2001/XMLSchema#string

Tawnya Hansen

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin-23 drives innate and T cell-mediated intestinal inflammation

Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Certolizumab pegol for the treatment of Crohn's disease

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

Crohn's disease

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Vedolizumab as induction and maintenance therapy for Crohn's disease.

IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

P304

989-994

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17474124.2016.1215912

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27450626

http://www.w3.org/2001/XMLSchema#string

P921

Crohn's disease